BGI began the research and development on HPV typing genetic testing technology useing next-generation high-throughput sequencing to accurate type 14 high-risk HPV’s (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,58,59, 66, 68)) which are highly correlated with cervical cancer as published by World Health Organization.